JP6611753B2 - アルツハイマー病の診断方法 - Google Patents

アルツハイマー病の診断方法 Download PDF

Info

Publication number
JP6611753B2
JP6611753B2 JP2017080646A JP2017080646A JP6611753B2 JP 6611753 B2 JP6611753 B2 JP 6611753B2 JP 2017080646 A JP2017080646 A JP 2017080646A JP 2017080646 A JP2017080646 A JP 2017080646A JP 6611753 B2 JP6611753 B2 JP 6611753B2
Authority
JP
Japan
Prior art keywords
gapdh
level
subject
disease
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017080646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018072313A5 (enExample
JP2018072313A (ja
Inventor
リン・チャイ−チン
ツァイ・チェン−ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Stem Biotech Co Ltd
Original Assignee
Bio Stem Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Stem Biotech Co Ltd filed Critical Bio Stem Biotech Co Ltd
Publication of JP2018072313A publication Critical patent/JP2018072313A/ja
Publication of JP2018072313A5 publication Critical patent/JP2018072313A5/ja
Application granted granted Critical
Publication of JP6611753B2 publication Critical patent/JP6611753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2017080646A 2016-10-26 2017-04-14 アルツハイマー病の診断方法 Active JP6611753B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/335,036 US11193933B2 (en) 2016-10-26 2016-10-26 Measuring GAPDH protein for diagnosis and treatment of alzheimer's disease
US15/335,036 2016-10-26

Publications (3)

Publication Number Publication Date
JP2018072313A JP2018072313A (ja) 2018-05-10
JP2018072313A5 JP2018072313A5 (enExample) 2018-06-21
JP6611753B2 true JP6611753B2 (ja) 2019-11-27

Family

ID=61969495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017080646A Active JP6611753B2 (ja) 2016-10-26 2017-04-14 アルツハイマー病の診断方法

Country Status (3)

Country Link
US (1) US11193933B2 (enExample)
JP (1) JP6611753B2 (enExample)
CN (1) CN107991490B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111198270B (zh) * 2018-11-16 2023-04-07 山东泽济生物科技有限公司 一种用于甘油醛-3-磷酸脱氢酶磁微粒化学发光检测试剂盒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022156A1 (en) * 1998-10-13 2000-04-20 Ono Pharmaceutical Co., Ltd. Antibody against glycerylaldehyde-3-phosphate dehydrogenase and utilization thereof
US20020172676A1 (en) 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
JP2005132738A (ja) * 2003-10-28 2005-05-26 Protein Express:Kk アルツハイマー病のタンパク質分子レベルにおける検出方法
AU2005274788A1 (en) * 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
DE102004052889A1 (de) * 2004-11-02 2006-05-11 Ruprecht-Karls-Universität Heidelberg Screeningverfahren zur Früherkennung des zerebralen Vasospasmus

Also Published As

Publication number Publication date
US20180113129A1 (en) 2018-04-26
US11193933B2 (en) 2021-12-07
CN107991490B (zh) 2021-04-30
JP2018072313A (ja) 2018-05-10
HK1250261A1 (zh) 2018-12-07
CN107991490A (zh) 2018-05-04

Similar Documents

Publication Publication Date Title
Tatebe et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
Kasuga et al. Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
Sparks et al. Tau is reduced in AD plasma and validation of employed ELISA methods
JP6927212B2 (ja) 軽度認知障害又はアルツハイマー型認知症の評価方法
Chen et al. Diagnostic accuracy of blood biomarkers for Alzheimer’s disease and amnestic mild cognitive impairment: A meta-analysis
JP6870679B2 (ja) アルツハイマー型認知症の将来の発症リスクの評価方法
CN102933966A (zh) 阿尔茨海默病的新型诊断制剂
Winder et al. Examining the association between blood‐based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort
MX2014012306A (es) Biomarcadores salivales especificos para deteccion de riesgo, diagnostico temprano, pronostico y vigilancia de las enfermedades de alzheimer y de parkinson.
Song et al. Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease?
JP2010537200A (ja) 改善されたアルツハイマー診断法
US20200166525A1 (en) Diagnosis-aiding method for determining neurodegenerative disease
JP6199880B2 (ja) 脳卒中の診断を補助するためのバイオマーカーに基づく方法およびバイオチップ
Sumbul et al. Renal cortical stiffness is markedly increased in pre-diabetes mellitus and associated with albuminuria
Tung et al. Cognitive impairment and its association with circulating biomarkers in patients with acute decompensated heart failure
JP6611753B2 (ja) アルツハイマー病の診断方法
JP4837734B2 (ja) 痴呆及び神経炎症性疾患の検出のためのＣＳＦ検出ｉｎｖｉｔｒｏ方法
TWI622771B (zh) 診斷阿茲海默症方法
KR102838949B1 (ko) 혈액 내 바이오마커 및 핵의학 검사를 활용한 인지단계 진행 예측 방법 및 시스템
WO2010005077A1 (ja) パーキンソン病の疾患関連たんぱく質およびその使用
EP3312611B1 (en) Method for diagnosis of alzheimer's disease
US20250191768A1 (en) Combination of biomarkers, and method for detecting cognitive dysfunction or risk thereof by using said combination
HK1250261B (zh) 诊断阿尔茨海默症的方法
Ghanbarian et al. CSF inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer’s disease spectrum
RU2821893C1 (ru) Способ дифференциальной прижизненной диагностики болезни альцгеймера

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611753

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250